

HR 5039

Life-Sustaining Prescription Drug Price Relief Act of 2019

Congress: 116 (2019–2021, Ended)

Chamber: House

Policy Area: Health

Introduced: Nov 12, 2019

Current Status: Sponsor introductory remarks on measure. (CR H8836)

Latest Action: Sponsor introductory remarks on measure. (CR H8836) (Nov 14, 2019)

Official Text: <https://www.congress.gov/bill/116th-congress/house-bill/5039>

Sponsor

Name: Rep. Lipinski, Daniel [D-IL-3]

Party: Democratic • **State:** IL • **Chamber:** House

Cosponsors

No cosponsors are listed for this bill.

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Nov 13, 2019
Ways and Means Committee	House	Referred To	Nov 12, 2019

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Life-Sustaining Prescription Drug Price Relief Act of 2019

This bill establishes a series of oversight and disclosure requirements relating to the prices of life-sustaining prescription drugs. Specifically, the bill requires the Department of Health and Human Services (HHS) to review at least annually all life-sustaining drugs for excessive pricing; HHS must also review prices upon petition. HHS must create a public database with its determinations for each drug and report its overall findings and related activities.

Under the bill, a price is considered excessive if the domestic average manufacturing price exceeds 110% of the average price for the drug in Canada, the United Kingdom, Germany, France, and Japan. If a price does not meet this criteria, or if pricing information is unavailable in at least three of the aforementioned countries, the price is still considered excessive if it is higher than reasonable in light of specified factors, including cost, revenue, and the size of the affected patient population.

The bill also requires drug manufacturers, subject to civil penalties, to (1) report specified financial information for life-sustaining drugs, including research and advertising expenditures; and (2) negotiate the prices of excessively priced life-sustaining drugs under the Medicare prescription drug benefit with HHS.

Actions Timeline

- **Nov 14, 2019:** Sponsor introductory remarks on measure. (CR H8836)
- **Nov 13, 2019:** Referred to the Subcommittee on Health.
- **Nov 12, 2019:** Introduced in House
- **Nov 12, 2019:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.